4=>{:variable=>"subtype",:name=>{"zh_tw"=>"乳癌分型<br/>(breast cancer subtype)","en"=>"breast cancer subtype"},:is_num=>0,:hint=>{'zh_tw'=>'','en'=>''},:comment_text=>{'zh_tw'=>'<p>HER2:第二型人類上皮成長因子接受器蛋白(HER2-enriched)過度表現型</p><p>若無分型資訊,請選擇“未知”選項,將以佔多數比例的管腔類進行預測。</p>','en'=>''},:choice_fields=>{"zh_tw"=>['管腔類','HER2','三陰性','未知'],"en"=>['Luminal-like','HER2','Triple negative','unknown']},:range=>[],:right=>1,:is_float=>0},
field:form_show_in_result,:type=>Hash,default:{0=>{:variable=>"hormone_therapy",:name=>{"zh_tw"=>"賀爾蒙治療","en"=>"Hormone/steroid therapy"},:is_num=>0,:hint=>{'zh_tw'=>'賀爾蒙治療適用於ER狀態為陽性之病人','en'=>'Hormone (endocrine) therapy is available when ER-status is positive'},:comment_text=>{'zh_tw'=>'','en'=>'<p>Hormone therapy, or endocrine therapy, involves a woman taking drugs to prevent the growth of tumour cells that are boosted by the hormone oestrogen. Drugs of this kind include tamoxifen (brand names include Nolvadex, Istabul, Valodex, and Soltamox) and aromatase inhibitors such as anastrozole, exemestane, and letrozole (brand names Arimidex, Aromasin, and Femara).</p>'+
'<p>Some hormone therapy drugs act by blocking the action of oestrogen on the cells and some work by lowering the amount of oestrogen in the body (NB hormone therapy for breast cancer is the opposite of hormone replacement therapy or HRT, which is taken by women to help INCREASE oestrogen levels to help deal with side-effects of the menopause).</p>'+
'<p>Treatments usually have the potential to cause harm as well as benefit. It is important to weigh up the risks of potential harm against the potential benefits of treatment in order to reach a decision. Some may cause more harm than benefit to some people.</p>'+
'<p>It is useful to switch between 1 and 5 years hormone therapy to compare the survival outcomes.</p>'},:choice_fields=>{"zh_tw"=>['否','是'],"en"=>['No','Yes']},:range=>[]},
field:text_descibe,type:Hash,default:{"zh_tw"=>"歡迎使用台灣準備乳癌癒後系統!<br/>若要開始 請在下方輸入相關資訊","en"=>" Welcome to The after breast cancer healing system of Taiwanprepare!\nTo start, please enter the relevant information below."}